1 week Ago By Defense World Staff
CureVac ( NASDAQ:CVAC – Free Report ) – Equities researchers at Leerink Partnrs upped their FY2025 earnings per share estimates for CureVac in a report released on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($0.
54) per share for the year, up from their previous estimate of ($0.60). The consensus estimate for CureVac’s current full-year earnings is $0.
72 per share. CureVac Stock Down 2.8 % CVAC opened at $3.
85 on Friday. The stock’s 50 day moving average price is $3.34 and its 200 day moving average price is $3.
20. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.
20 and a quick ratio of 6.19. The stock has a market cap of $861.
94 million, a P/E ratio of 7.00 and a beta of 2.50.
CureVac has a 12 month low of $2.21 and a 12 month high of $5.28.
Hedge Funds Weigh In On CureVac CureVac Company Profile ( Get Free Report ) CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. See Also Five stocks we like better than CureVac How to Evaluate a Stock Before Buying Bloom Energy: Powering the Future With Decentralized Energy Transportation Stocks Investing Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul 3 Small Caps With Big Return Potential Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter .
.
